Lupin Launches Generic Cymbalta

Lupin Pharmaceuticals, Inc., the U.S. subsidiary of Pharma Major Lupin Limited, has launched Duloxetine Hydrochloride Delayed-release (HCl DR) Capsules 20 mg, 30 mg and 60 mg strengths. The company received final approval to market its Duloxetine HCl DR Capsules USP, 20 mg, 30 mg, 40 mg and 60 mg strengths from the FDA yesterday.

Lupin’s Duloxetine HCl DR Capsules are the generic equivalent of Lilly‘s Cymbalta Delayed-release Capsules at those same dosages. Duloxetine HCl DR Capsules are indicated for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD) and management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy.